- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06066333
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Safety and Immunological Effects of Ablative Radiotherapy Followed by Pembrolizumab in Patients With Advanced Adrenocortical Carcinoma
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Nitya Raj, MD
- Phone Number: 646-888-4849
- Email: rajn@mskcc.org
Study Contact Backup
- Name: Diane Reidy-Lagunes, MD
- Phone Number: 646-888-4185
- Email: reidyd@mskcc.org
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Recruiting
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
-
Contact:
- Nitya Raj, MD
- Phone Number: 646-888-4849
-
Middletown, New Jersey, United States, 07748
- Recruiting
- Memorial Sloan Kettering Monmouth (All protocol activities)
-
Contact:
- Nitya Raj, MD
- Phone Number: 646-888-4849
-
Montvale, New Jersey, United States, 07645
- Recruiting
- Memorial Sloan Kettering Bergen (All Protocol Activities)
-
Contact:
- Nitya Raj, MD
- Phone Number: 646-888-4849
-
-
New York
-
Commack, New York, United States, 11725
- Recruiting
- Memorial Sloan Kettering Suffolk-Commack
-
Contact:
- Nitya Raj, MD
- Phone Number: 646-888-4849
-
Harrison, New York, United States, 10604
- Recruiting
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Contact:
- Nitya Raj, MD
- Phone Number: 646-888-4849
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center (All protocol activities)
-
Contact:
- Nitya Raj, MD
- Phone Number: 646-888-4849
-
Uniondale, New York, United States, 11553
- Recruiting
- Memorial Sloan Kettering Nassau (All Protocol Activities)
-
Contact:
- Nitya Raj, MD
- Phone Number: 646-888-4849
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be willing and able to provide written informed consent for the trial.
- Be ≥ 15 years of age on day of signing informed consent.
- Have histologically- or cytologically- confirmed metastatic ACC with symptomatic liver metastases.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
Adequate performance status:
- Patients < 16 years of age: Lansky ≥ 50%
- Patients ≥ 16 years of age: Karnofsky ≥ 50%
- Have measurable disease based on RECIST v1.1.
- Have radiologic documentation of extrahepatic tumor, defined as extrahepatic metastases.
- Consent for use of archived tissue for research purposes. Archival tissue (1 block or 20 unstained slides) will be requested, when available.
- Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 28 days of treatment initiation.
Table 1: Adequate Organ Function Laboratory Value
Hematological Absolute neutrophil count (ANC) ≥1,500 / mcL Platelets ≥100,000 / mcL
Renal Serum creatinine ≤1.5 X upper limit of normal (ULN) OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
*Creatinine clearance should be calculated per institutional standard.
Hepatic Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN AST (SGOT) and ALT (SGPT) ≤ 5 X ULN
Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- Female subjects of childbearing potential should have a negative serum pregnancy test within 72 hours prior to beginning treatment on study. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 10.6.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free of menses for >1 year.
- Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
Exclusion Criteria:
- Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to study Day 1 (the first day of ablative RT).
- Has undergone radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (to include Y90).
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study Day 1. The use of physiologic doses of corticosteroids for adrenal and pituitary insufficiency is not considered a form of systemic steroid therapy and would not exclude a subject from the study.
- Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. The use of non-immunotherapy monoclonal antibodies (such as dupilumab (for eczema), omalizumab (for urticaria), benralizumab (for asthma)) would not exclude a subject from the study.
- Has had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study.
- If subject underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Has known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to beginning treatment on study and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for brain metastases for at least 7 days prior to study Day 1. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study. Subjects that have adrenal or pituitary insufficiency that require physiologic corticosteroid replacement therapy would not be excluded from the study. Subjects who are on mitotane for control of hormonal symptoms for their disease at the time of eligibility assessment can continue on mitotane during the course of the study.
- Has evidence of interstitial lung disease or history of (non-infectious) pneumonitis that required steroids or current pneumonitis. 11. Has an active infection requiring systemic therapy. 12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 14. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- Has received a live vaccine or live-attenuated vaccine within 30 days prior to study Day 1. Administration of killed vaccine is allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants with Adrenocortical Carcinoma
Participants with histologically proven metastatic Adrenocortical Carcinoma/ACC with both intra-hepatic and extra-hepatic sites of disease.
|
All participants will first undergo ablative RT
Other Names:
After completion of ablative RT, all subjects may begin pembrolizumab treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants evaluated for AEs
Time Frame: up to 1 year
|
The primary objective of this pilot study is to evaluate the safety of treatment with ablative Radiotherapy/RT followed by pembrolizumab in patients with advanced Adrenocortical Carcinoma/ACC by evaluating treatment related adverse events.
AEs will be recorded according to "Common Terminology Criteria for Adverse Events" v5.0 (CTCAE).
|
up to 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nitya Raj, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Adrenal Gland Diseases
- Adrenal Cortex Neoplasms
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Carcinoma
- Adrenocortical Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- 23-272
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adrenocortical Carcinoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical CarcinomaUnited States
-
Dartmouth-Hitchcock Medical CenterM.D. Anderson Cancer Center; Dana-Farber Cancer Institute; AstraZeneca; Kentuckiana...CompletedNonresectable Adrenocortical CarcinomaUnited States
-
Latin American Cooperative Oncology GroupNot yet recruitingCarcinoma Adrenal | Carcinoma, Adrenocortical RecurrentBrazil
-
Burzynski Research InstituteTerminatedStage IV Adrenocortical CarcinomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAdrenocortical Carcinoma
-
National Cancer Institute (NCI)CompletedAdrenal Cortex NeoplasmsUnited States
-
National Cancer Institute (NCI)RecruitingNeuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinomas | Carcinoma, Adrenal Cortical | Carcinoma, AdrenocorticalUnited States
-
University Medical Center GroningenRadboud University Medical Center; Maastricht University Medical Center; UMC... and other collaboratorsRecruitingAdrenocortical Carcinoma | Adrenal IncidentalomaNetherlands
-
National Cancer Institute (NCI)PfizerCompletedAdrenal Cortex NeoplasmsUnited States
Clinical Trials on Ablative Radiotherapy
-
Lawson Health Research InstituteOntario Institute for Cancer ResearchActive, not recruiting
-
Barts & The London NHS TrustRecruitingHeart Failure | Ventricular Tachycardia | Radiotherapy; Complications | Structural Heart AbnormalityUnited Kingdom
-
University Health Network, TorontoRecruiting
-
Second Xiangya Hospital of Central South UniversityCompletedSterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy (SELECT)Hypertrophic Obstructive CardiomyopathyChina
-
Lawson Health Research InstituteUniversity of British Columbia; Western University, Canada; London Health Sciences...Active, not recruitingNon Small Cell Lung Cancer | Interstitial Lung DiseaseCanada, United Kingdom
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Stanford UniversityVarian, a Siemens Healthineers CompanyActive, not recruitingEmphysemaUnited States
-
Amsterdam UMC, location VUmcDutch Cancer SocietyRecruitingBreast CancerNetherlands
-
University of Texas Southwestern Medical CenterWithdrawnTachycardia, VentricularUnited States